Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia

Isariyaphong Kotikula | Nithi Thinrungroj | Kanokwan Pinyopornpanish | Phuripong Kijdamrongthum | Apinya Leerapun | Taned Chitapanarux | Satawat Thongsawat | Ong-Ard Praisontarangkul

Background: Currently, central neuromodulators are among the therapeutic options for the treatment of functional dyspepsia (FD). Pregabalin, a gabapentinoid, is a neuromodulator that could potentially improve visceral hypersensitivity in FD patients.
Aim: To assess the efficacy and safety of pregabalin for the treatment of FD
Methods: We performed a randomised placebo-controlled study including FD patients who did not respond to proton pump inhibitors. Patients were randomly assigned to receive pregabalin (75 mg daily) or placebo for 8 weeks. The primary outcome was an adequate relief response rate. The secondary outcomes were improvement in quality of life, pain scores in divided categories, and safety profile.
Results: Of 72 patients enrolled, 34 received pregabalin and 38 received placebo.
The self-reported adequate relief rates in the pregabalin and placebo groups were 70.6% and 42.1% at week 4 (P = 0.02), and 70.6% and 44.7% at week 8 (P = 0.03), respectively. The reduction in global symptoms in the pregabalin and placebo groups were 11.7 ± 10.6 and 3.7 ± 8.9 p oints a t w eek 4 (P < 0.01) and 15.1 ± 12.2 and 8.0 ± 10.2 points at week 8 (P = 0.01), respectively. Pregabalin improved the overall quality of life (P = 0.03). The most common adverse event with pregabalin was dizziness,
occurring in 51.6% of patients.
Conclusions: Pregabalin led to significant alleviation of dyspeptic symptoms, especially in patients with predominant epigastric pain . Thaiclinicaltrials.org #TCTR20200404002.